The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (https://lit.eu) – is a biomedical research center focusing on translational immunology in the fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the LIT is to develop innovative and efficient cellular immune therapeutics in these areas. Our own GMP laboratories and close networking with University and University Hospital offer excellent opportunities for clinical translation of novel immune cell products.
The Clinical Translation Group “T Cell Fitness” at the LIT is recruiting a
Starting January 2027. The position is initially limited to three years, with the possibility of extension.
About the group:
The T Cell Fitness group at the Leibniz Institute for Immunotherapy (LIT) in Regensburg develops innovative platform technologies to improve T-cell-based immunotherapies for solid tumors, with a strong focus on clinical translation.
By combining T-cell engineering, molecular biology, functional assays, and preclinical tumor models, we aim to enhance T-cell fitness, persistence, and antitumor activity within the challenging tumor microenvironment. Our goal is to overcome current limitations of adoptive T-cell therapies and advance promising strategies toward clinical application.
Your Role:
You will develop engineered T-cell therapies to enhance their fitness and antitumor activity in solid tumors. Your responsibilities will include:
Your profile:
Master's degree in biology, molecular medicine or a related field
At least two years of hands-on experience in preclinical solid tumor models including both murine syngeneic and xenograft tumor models
Approved laboratory animal science training covering both basic experimental procedures and surgical techniques (e.g. relevant FELASA-aligned qualifications)
Experience in the cultivation and genetic modification of both primary human and murine T cells
Practical experience in viral transduction and the generation of stable genetically modified cell lines
Experience in establishing and performing in vitro cytotoxicity assays, including longitudinal killing assays and repeated tumor rechallenge experiments using Incucyte® and xCELLigence® devices
Experience in the identity proof of engineered immune cells using multiparameter flow cytometry, ELISA and qPCR
Experience in the planning, execution, and analysis of in vivo tumor experiments, including tumor monitoring, tissue collection, and downstream immunological analyses
Strong interest in T-cell engineering, immune cell fitness, and the development of next-generation platform technologies for solid tumors
Familiarity with GCP and GMP principles, including documented training or certification in the relevant regulatory standards
Excellent oral and written communication skills in English
Ability to work independently, combined with a collaborative and solution-oriented mindset
We offer:
An international cutting-edge research environment that offers exciting and diverse opportunities
Perspectives for further scientific qualification
Flexible working hours
Flat hierarchies and short decision-making processes
A highly motivated and cooperative team
Possibility to enroll in the RIGeL graduate school
Company pension scheme (VBL)
Annual special payment
Capital-forming benefits
Job ticket and more
The remuneration is based on TV-L (E13, 65%).
The LIT places particular emphasis on promoting a healthy work-life balance.
Disabled applicants (m/f/d) with equal qualifications will receive preferential treatment within the recruitment procedure. Please refer to your disability status already in your application.
Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.
For more information, please contact Assoc. Prof. Dr. Dr. Roland Schelker (roland.schelker@lit.eu).
We are looking forward to receiving your detailed application. Please apply via our Online - Application Portal quoting the reference RS-2026-1.
The application deadline is 02.12.2026.